{"protocolSection": {"identificationModule": {"nctId": "NCT01118312", "orgStudyIdInfo": {"id": "ALAACRC-11"}, "secondaryIdInfos": [{"id": "R01 HL089464-01A2", "type": "OTHER", "domain": "NIH/NHLBI"}, {"id": "R01 HL00895101-01A2", "type": "OTHER", "domain": "NIH/NHLBI"}], "organization": {"fullName": "JHSPH Center for Clinical Trials", "class": "OTHER"}, "briefTitle": "Study of Asthma and Nasal Steroids", "officialTitle": "Study of Asthma and Nasal Steroids for the American Lung Association-Airways Clinical Research Centers", "acronym": "STAN"}, "statusModule": {"statusVerifiedDate": "2015-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-09"}, "primaryCompletionDateStruct": {"date": "2014-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-04-28", "studyFirstSubmitQcDate": "2010-05-05", "studyFirstPostDateStruct": {"date": "2010-05-06", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-09-24", "resultsFirstSubmitQcDate": "2015-10-29", "resultsFirstPostDateStruct": {"date": "2015-11-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-10-29", "lastUpdatePostDateStruct": {"date": "2015-11-30", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "JHSPH Center for Clinical Trials", "class": "OTHER"}, "collaborators": [{"name": "National Institutes of Health (NIH)", "class": "NIH"}, {"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The trial will study the effectiveness of nasal steroids for the treatment of chronic rhinitis and/or sinusitis on asthma control.", "detailedDescription": "Previous trials completed by the American Lung Association-Airways Clinical Research Centers (ALA-ACRC) network have identified rhinitis and/or sinusitis as a significant co-morbidity in people with asthma that affects asthma symptoms and control. The objective of this clinical trial is to determine if treatment of chronic rhinitis and/or sinusitis with nasal steroids improves control of asthma in children and adults. Although chronic rhinitis and/or sinusitis have been associated with poor asthma control and increased health care utilization, the effect of treating these diseases on asthma control is not known. This will be a six-month randomized, double-blinded, placebo-controlled trial enrolling 380 participants, 190 children and 190 adults, with poorly controlled asthma and chronic rhinitis/sinusitis. Participants will be randomized to receive nasal steroid or a matching placebo in addition to their regular asthma treatments. The primary objective of the trial will be to evaluate whether the addition of treatment with nasal steroids improves asthma control. We will perform allergy skin testing on all participants and keep a record of pollen counts at all centers, to determine if allergy is an important factor in the response to nasal steroid in participants."}, "conditionsModule": {"conditions": ["Asthma", "Rhinitis", "Sinusitis"], "keywords": ["Asthma", "Rhinitis", "Sinusitis", "Chronic", "ACRC", "STAN", "Nasal steroid", "Mometasone", "Nasal spray"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER"]}}, "enrollmentInfo": {"count": 388, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Nasal Steroid", "type": "ACTIVE_COMPARATOR", "description": "Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day", "interventionNames": ["Drug: Mometasone Furoate monohydrate"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Intranasal placebo, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Mometasone Furoate monohydrate", "description": "Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day for 6 months", "armGroupLabels": ["Nasal Steroid"], "otherNames": ["Nasonex"]}, {"type": "OTHER", "name": "Placebo", "description": "Intranasal placebo spray", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Asthma Control Test (ACT)", "description": "Asthma Control Test for adults (score range: 5-25); higher score indicates better asthma control", "timeFrame": "24 weeks"}], "secondaryOutcomes": [{"measure": "Childhood Asthma Control Test", "description": "Childhood Asthma Control Test (score range: 0-27); higher score indicates better asthma control", "timeFrame": "24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Physician diagnosed asthma\n* At least 12% increase in forced expiratory volume at one second (FEV1) after 2-4 puffs of albuterol or positive methacholine challenge (20% fall in FEV1 at less than 16 mg/ml methacholine); either of these can be available from the last 2 years before enrollment\n* Poorly controlled asthma as documented by a score of 19 or less on the Asthma Control Test (ACT) for participants 12 and older, and a Childhood Asthma Control Test (C-ACT) for 6-11 years(both V1 and V2).\n* Chronic symptoms of rhinitis and sinusitis as measured by a mean score of 1 on the Sino-nasal questionnaire\n* Males and females, age 6 and older\n\nExclusion Criteria:\n\n* Co-morbidity that predisposes to complicated rhino-sinusitis (e.g., cystic fibrosis, insulin dependent diabetes mellitus, immunodeficiency disorder)\n* Chronic diseases (other than asthma) that in the opinion of the investigator would prevent participation in the trial or put the participant at risk by participation, e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney or nervous system.\n* History of sinus surgery in last 6 months\n* Systemic/nasal steroids within last 4 weeks\n* Anti-leukotriene medication\n* History of upper airway symptoms for less than 8 weeks at the time of enrollment\n* Fever \\> 38.3 degrees Celsius or patient history of fever in last 10 days\n* Greater than 10 pack year smoking history or active smoking within the last 6 months\n* FEV1 \\< 50% predicted\n* Females of childbearing potential that are pregnant or lactating, or unwilling to practice an adequate birth control method\n* Allergy or intolerance to nasal mometasone\n* Cataracts, history of glaucoma, or other conditions resulting in increased intraocular pressure\n* Any investigational drug in the last 6 weeks\n* Inability to comply with study procedures, including:\n\n  * Inability or unwillingness to provide informed consent (or assent in the case of a minor)\n  * Inability to take study medication\n  * Inability to perform baseline measurements\n  * Completion of less than 10 of the 14 days of screening period diary entry\n  * Inability to be contacted by phone\n  * Intention to move out of the area within 6 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Anne Dixon, MD", "affiliation": "University of Vermont", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Arizona", "city": "Tucson", "state": "Arizona", "zip": "85724", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "University of California, San Diego", "city": "San Diego", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "National Jewish Health", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Nemours Children's Clinic", "city": "Jacksonville", "state": "Florida", "zip": "32207", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Univeristy of Miami School of Medicine", "city": "Miami", "state": "Florida", "zip": "33136", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "University of South Florida College of Medicine", "city": "Tampa", "state": "Florida", "zip": "33613", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Northwestern Memorial Hospital", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Indiana University", "city": "Indianapolis", "state": "Indiana", "zip": "46202", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Louisiana State University Health Sciences Center", "city": "New Orleans", "state": "Louisiana", "zip": "70112", "country": "United States", "geoPoint": {"lat": 29.95465, "lon": -90.07507}}, {"facility": "University of Missouri, Kansas City School of Medicine", "city": "Kansas City", "state": "Missouri", "zip": "64108", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Washington University School of Medicine", "city": "St. Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "North Shore-Long Island Jewish Health System", "city": "New Hyde Park", "state": "New York", "zip": "11040", "country": "United States", "geoPoint": {"lat": 40.7351, "lon": -73.68791}}, {"facility": "New York University School of Medicine", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "New York Medical College", "city": "Valhalla", "state": "New York", "zip": "10595", "country": "United States", "geoPoint": {"lat": 41.07482, "lon": -73.77513}}, {"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Davis Heart and Lung Research Institute", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Baylor College of Medicine", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Vermont Lung Center at the University of Vermont", "city": "Burlington", "state": "Vermont", "zip": "05405", "country": "United States", "geoPoint": {"lat": 44.47588, "lon": -73.21207}}, {"facility": "Univeristy of Virginia", "city": "Charlottesville", "state": "Virginia", "zip": "22908", "country": "United States", "geoPoint": {"lat": 38.02931, "lon": -78.47668}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "ALA-ACRC Webpage", "url": "http://www.cctrials.org/alaacrc"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Nasal Steroid", "description": "Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day\n\nMometasone Furoate monohydrate: Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day for 6 months"}, {"id": "FG001", "title": "Placebo", "description": "Intranasal placebo, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day\n\nPlacebo: Intranasal placebo spray"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "189"}, {"groupId": "FG001", "numSubjects": "199"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "155"}, {"groupId": "FG001", "numSubjects": "164"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "35"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "33"}, {"groupId": "FG001", "numSubjects": "32"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Nasal Steroid", "description": "Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day\n\nMometasone Furoate monohydrate: Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day for 6 months"}, {"id": "BG001", "title": "Placebo", "description": "Intranasal placebo, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day\n\nPlacebo: Intranasal placebo spray"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "189"}, {"groupId": "BG001", "value": "199"}, {"groupId": "BG002", "value": "388"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "79"}, {"groupId": "BG002", "value": "151"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "117"}, {"groupId": "BG001", "value": "120"}, {"groupId": "BG002", "value": "237"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "105"}, {"groupId": "BG001", "value": "106"}, {"groupId": "BG002", "value": "211"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "93"}, {"groupId": "BG002", "value": "177"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Asthma Control Test (ACT)", "description": "Asthma Control Test for adults (score range: 5-25); higher score indicates better asthma control", "populationDescription": "Analysis of adult (18 and above) Asthma Control Scores", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Nasal Steroid", "description": "Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day\n\nMometasone Furoate monohydrate: Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day for 6 months"}, {"id": "OG001", "title": "Placebo", "description": "Intranasal placebo, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day\n\nPlacebo: Intranasal placebo spray"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "117"}, {"groupId": "OG001", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.95", "spread": "0.31"}, {"groupId": "OG001", "value": "2.44", "spread": "0.38"}]}]}]}, {"type": "SECONDARY", "title": "Childhood Asthma Control Test", "description": "Childhood Asthma Control Test (score range: 0-27); higher score indicates better asthma control", "populationDescription": "Analysis of Children (less than 18 years old) Childhood Asthma Control Test scores", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on a scale", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Nasal Steroid", "description": "Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day\n\nMometasone Furoate monohydrate: Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day for 6 months"}, {"id": "OG001", "title": "Placebo", "description": "Intranasal placebo, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day\n\nPlacebo: Intranasal placebo spray"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.15", "spread": "0.64"}, {"groupId": "OG001", "value": "4.53", "spread": "0.65"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Nasal Steroid", "description": "Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day\n\nMometasone Furoate monohydrate: Intranasal mometasone, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day for 6 months", "seriousNumAffected": 2, "seriousNumAtRisk": 189, "otherNumAffected": 105, "otherNumAtRisk": 179}, {"id": "EG001", "title": "Placebo", "description": "Intranasal placebo, 1 spray (age \\< 12 yr) or 2 sprays (age \\>= 12 yrs) each nostril once a day\n\nPlacebo: Intranasal placebo spray", "seriousNumAffected": 9, "seriousNumAtRisk": 199, "otherNumAffected": 127, "otherNumAtRisk": 187}], "seriousEvents": [{"term": "Depression (hospitalized)", "organSystem": "Psychiatric disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 189}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 199}]}, {"term": "Anaphylactic reaction", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 189}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 199}]}, {"term": "Dental abscess", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 189}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 199}]}, {"term": "Headache and high blood pressure", "organSystem": "Vascular disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 189}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 199}]}, {"term": "Dehydration", "organSystem": "General disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 189}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 199}]}, {"term": "asthma exacerbation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 189}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 199}]}, {"term": "pneumonia", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 189}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 199}]}, {"term": "Fungus ball of the sinus requiring surgery", "organSystem": "Surgical and medical procedures", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 189}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 199}]}, {"term": "appendicitis", "organSystem": "Infections and infestations", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 189}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 199}]}], "otherEvents": [{"term": "Headache", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 45, "numAtRisk": 140}, {"groupId": "EG001", "numAffected": 56, "numAtRisk": 148}]}, {"term": "Sore throat", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 22, "numAtRisk": 174}, {"groupId": "EG001", "numAffected": 34, "numAtRisk": 175}]}, {"term": "Nasal bleed", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 176}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 184}]}, {"term": "Nasal pain", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 162}, {"groupId": "EG001", "numAffected": 44, "numAtRisk": 168}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 172}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 180}]}, {"term": "Itching", "organSystem": "Skin and subcutaneous tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 157}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 165}]}, {"term": "Dizzy", "organSystem": "Ear and labyrinth disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 172}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 181}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 178}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 184}]}, {"term": "Trouble breathing", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 42, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 55, "numAtRisk": 152}]}, {"term": "Swelling", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 175}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 183}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 39, "numAtRisk": 133}, {"groupId": "EG001", "numAffected": 44, "numAtRisk": 157}]}, {"term": "Dysmenorrhea", "organSystem": "Reproductive system and breast disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Counts include the number of individuals who experienced a moderate or severe symptom at follow up. Individuals who had the symptom (moderate or severe) at baseline are excluded as are those with no follow-up data on the adverse event.", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 116}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 112}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Razan Yasin", "organization": "Johns Hopkins University", "email": "ryasin1@jhu.edu", "phone": "443-287-5796"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000012220", "term": "Rhinitis"}, {"id": "D000012852", "term": "Sinusitis"}, {"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000012141", "term": "Respiratory Tract Infections"}, {"id": "D000007239", "term": "Infections"}, {"id": "D000009668", "term": "Nose Diseases"}, {"id": "D000010038", "term": "Otorhinolaryngologic Diseases"}, {"id": "D000010254", "term": "Paranasal Sinus Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M15049", "name": "Rhinitis", "asFound": "Rhinitis", "relevance": "HIGH"}, {"id": "M15657", "name": "Sinusitis", "asFound": "Sinusitis", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M14978", "name": "Respiratory Tract Infections", "relevance": "LOW"}, {"id": "M12604", "name": "Nose Diseases", "relevance": "LOW"}, {"id": "M12961", "name": "Otorhinolaryngologic Diseases", "relevance": "LOW"}, {"id": "M13167", "name": "Paranasal Sinus Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "BC09", "name": "Ear, Nose, and Throat Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068656", "term": "Mometasone Furoate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "Sagramostim", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}